For a complete listing of publications click here.
Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK. Emerging Strategies for Treating Brain Metastases from Breast Cancer.
Cancer Cell. 2015; 27(2):163-175.
Jain, RK. An indirect way to tame cancer. Scientific American 2014; 310: 46–53.
Jain RK. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 2014; 26: 605–622,
M Snuderl, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell, 2013; 152: 1065–1076.
Carmeliet P, Jain, R; Molecular Mechanisms and clinical applications; Nature 2011 May 19; 473(7347): 298-307.
Jain RK, Stylianopoulos T; Delivering nanomedicine to solid tumors; Nature Rev Clin Oncol 2010Nov.; 7(11); 653-64.
S. R. Plotkin, A. O. Stemmer-Rachamimov, F. G. Barker II, C. Halpin, T. P. Padera, A. Tyrell, A. G. Sorensen, R. K. Jain and E. di Tomaso, “Hearing improvement after bevacizumab in patients with neurofibromatosis 2,” The New England Journal of Medicine 2009; 361: 24-33.
Jain RK. Taming vessels to treat cancer. Scientific American 2008; 298: 56-63.
Batchelor TT, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
Jain RK. Normalization of the tumor vasculature: An emerging concept in anti-angiogenic therapy. Science 2005; 307:58-62
Winkler F, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553-562.